Intelligence Feed event · Policy · 2026-09-16

    CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth

    Question

    CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth

    Direct answer

    Commercial forecasts for chimeric antigen receptor (CAR) T-cell therapies point to steady multi-year expansion across hematologic oncology indications. The Non-Hodgkin Lymphoma CAR-T market is projected to grow at a 7% compound annual growth rate through 2036, building upon a 2025 market valuation of $3.20 billion across seven major geographies. Concurrently, the market for acute lymphoblastic leukemia (ALL) cellular therapies is forecasted to expand at a 6.8% CAGR over the same decade, growing from a $300 million baseline in 2025. Market momentum is supported by commercial uptake of approved therapies including Kymriah (Novartis), Tecartus (Gilead Sciences), and Aucatzyl (Autolus Therapeutics). Clinical pipeline transitions from autologous to allogeneic off-the-shelf platforms, coupled with label expansions into earlier lines of treatment, represent the primary catalysts for sustained revenue expansion across biopharma oncology portfolios.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-16
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth”, revision 1, evidence through 2026-09-16. https://marketontology.com/market-events/2026-09-16/car-t-oncology-market-expands-as-all-and-lymphoma-therapies-target-long-term-gro-9af5a2

    POLICY
    CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
    Commercial forecasts for chimeric antigen receptor (CAR) T-cell therapies point to steady multi-year expansion across hematologic oncology indications. The Non-Hodgkin Lymphoma CAR-T market is projected to grow at a 7% compound annual growth rate through 2036, building upon a 2025 market valuation of $3.20 billion across seven major geographies. Concurrently, the market for acute lymphoblastic leukemia (ALL) cellular therapies is forecasted to expand at a 6.8% CAGR over the same decade, growing from a $300 million baseline in 2025. Market momentum is supported by commercial uptake of approved therapies including Kymriah (Novartis), Tecartus (Gilead Sciences), and Aucatzyl (Autolus Therapeutics). Clinical pipeline transitions from autologous to allogeneic off-the-shelf platforms, coupled with label expansions into earlier lines of treatment, represent the primary catalysts for sustained revenue expansion across biopharma oncology portfolios.
    GILDNVSAUTL
    Impact
    60
    SEP 16
    SIG
    78%
    GILDNVSAUTL
    CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
    Commercial forecasts for chimeric antigen receptor (CAR) T-cell therapies point to steady multi-year expansion across hematologic oncology indications. The Non-Hodgkin Lymphoma CAR-T market is projected to grow at a 7% compound annual growth rate through 2036, building upon a 2025 market valuation of $3.20 billion across seven major geographies. Concurrently, the market for acute lymphoblastic leukemia (ALL) cellular therapies is forecasted to expand at a 6.8% CAGR over the same decade, growing from a $300 million baseline in 2025. Market momentum is supported by commercial uptake of approved therapies including Kymriah (Novartis), Tecartus (Gilead Sciences), and Aucatzyl (Autolus Therapeutics). Clinical pipeline transitions from autologous to allogeneic off-the-shelf platforms, coupled with label expansions into earlier lines of treatment, represent the primary catalysts for sustained revenue expansion across biopharma oncology portfolios.
    → Earlier-line indication approvals and allogeneic cell therapy adoption expand commercial revenue runways for GILD and NVS CAR-T oncology portfolios.
    Impact
    Commercial forecasts for chimeric antigen receptor (CAR) T-cell therapies point to steady multi-year expansion across hematologic oncology indications. The Non-Hodgkin Lymphoma CAR-T market is projected to grow at a 7% compound annual growth rate through 2036, building upon a 2025 market valuation of $3.20 billion across seven major geographies. Concurrently, the market for acute lymphoblastic leukemia (ALL) cellular therapies is forecasted to expand at a 6.8% CAGR over the same decade, growing from a $300 million baseline in 2025. Market momentum is supported by commercial uptake of approved therapies including Kymriah (Novartis), Tecartus (Gilead Sciences), and Aucatzyl (Autolus Therapeutics). Clinical pipeline transitions from autologous to allogeneic off-the-shelf platforms, coupled with label expansions into earlier lines of treatment, represent the primary catalysts for sustained revenue expansion across biopharma oncology portfolios.
    Affected
    GILDNVSAUTL
    Transmission
    Earlier-line indication approvals and allogeneic cell therapy adoption expand commercial revenue runways for GILD and NVS CAR-T oncology portfolios.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GILDoncology cell therapy volume growth via Tecartus label expansionUp1-3mGilead's Tecartus cited among approved therapies driving market growth from $3.20B base.
    NVSKymriah revenue runway expansion across hematologic indicationsUp1-3mNovartis Kymriah listed as key driver in ALL and lymphoma market expansion.
    AUTLcommercial adoption of Aucatzyl in acute lymphoblastic leukemiaUp1-3mAutolus Aucatzyl identified as emerging therapy in CAR-T ALL market.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month